# Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/gemcitabine-and-docetaxel-in-patients-with-unresectable-leiomyosarcoma-results/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Martee L. Hensley,Robert G. Maki,Ennapadam Venkatraman,Gennifer Geller,Meghan Lovegren,Carol Aghajanian,Paul Sabbatini,William P. Tong,Richard R. Barakat,David R. Spriggs |
| Citations | 690 |
| DOI | 10.1200/jco.2002.11.050 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2161170571 |
| PMID | 12065559 |
| Type | article |
| Year | 2002 |

## Paper authors

- [Carol Aghajanian](https://scholariq.org/researchers/carol-aghajanian/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [Uterine Myomas and Treatments](https://scholariq.org/topics/uterine-myomas-and-treatments/)

## Paper topics

- [Uterine Myomas and Treatments](https://scholariq.org/topics/uterine-myomas-and-treatments/)
- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.